Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin

Title:Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin

Volume: 19 Issue: 12

Author(s): Feng Sun, Abdul Sami Shaikh, Juan Wang, Hui Gao, Zhifang Yang, Zhendong Wang, Yan Li, Fengshan Wang and Haining Tan*

Affiliation:

• National Glycoengineering Research Center, School of Pharmaceutical Sciences, Shandong University, Jinan 250012,China

Keywords: Polysulfated heparin, endostatin, cellular uptake, anti-angiogenesis activity, pharmacokinetics, anti-angiogenesis activity.

Abstract: Background: Endostatin (ES) is a promising anti-angiogenesis protein and has been approved for the treatment of non-small cell lung cancer, but short half-life, poor stability and nonspecific delivery caused great pain to patients and produced unsatisfactory treatment effectiveness.

Objective: In this work, in order to overcome these disadvantages, ES was covalently modified by polysulfated heparin (PSH) with the expectancy of longer half-life, higher anti-angiogenesis activity and better cellular uptake.

Methods: To characterize the cellular uptake, flow cytometry and confocal laser scanning microscopy were used to study the intracellular localization of fluorescein isothiocyanate-labeled ES and PSH-ES in EAhy926 endothelial cells. Zebrafish model was used to study the anti-angiogenesis activities of ES and its derivatives in vivo. The 125I-radiolabeled ES and PSH-ES were administered to healthy BALC/c mice for the pharmacokinetics study.

Results: Compared with ES, better cellular uptake effects were detected in PSH-ES group. Both ES and PSH-ES showed inhibition on the intersegmental vessels formation, while PSH-ES displayed a higher one. The half-life of PSH-ES was lengthened and area under the curve (AUC) was increased. At the same time, ES and PSH-ES were both widely and rapidly distributed in the lungs, livers, kidneys and hearts with little difference.

Conclusion: The results indicated that PSH displayed good properties as a novel glyco-modifier for protein and peptide. The results also showed that PSH-ES displayed better cellular uptake, higher antiangiogenesis activity and prolonged half-life, which would lead to better anti-tumour effects.

Cite this article as:

Sun Feng, Shaikh Sami Abdul , Wang Juan , Gao Hui , Yang Zhifang , Wang Zhendong , Li Yan , Wang Fengshan and Tan Haining *, Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin, Current Pharmaceutical Biotechnology 2018; 19 (12) . https://dx.doi.org/10.2174/1389201020666181120164753